No-reflow phenomenon overview

Jump to navigation Jump to search

No-reflow phenomenon Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Electrocardiography

Coronary Angiography

Myocardial Contrast Echocardiography

Coronary Doppler Imaging

Other Imaging Findings

Treatment

Medical Therapy

Prevention

Case Studies

Case #1

No-reflow phenomenon overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of No-reflow phenomenon overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on No-reflow phenomenon overview

CDC onNo-reflow phenomenon overview

No-reflow phenomenon overview in the news

Blogs on No-reflow phenomenon overview

Directions to Hospitals Treating No-reflow phenomenon

Risk calculators and risk factors for No-reflow phenomenon overview

WikiDoc Resources for No-reflow phenomenon overview

Articles

Most recent articles on No-reflow phenomenon overview

Most cited articles on No-reflow phenomenon overview

Review articles on No-reflow phenomenon overview

Articles on No-reflow phenomenon overview in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on No-reflow phenomenon overview

Images of No-reflow phenomenon overview

Photos of No-reflow phenomenon overview

Podcasts & MP3s on No-reflow phenomenon overview

Videos on No-reflow phenomenon overview

Evidence Based Medicine

Cochrane Collaboration on No-reflow phenomenon overview

Bandolier on No-reflow phenomenon overview

TRIP on No-reflow phenomenon overview

Clinical Trials

Ongoing Trials on No-reflow phenomenon overview at Clinical Trials.gov

Trial results on No-reflow phenomenon overview

Clinical Trials on No-reflow phenomenon overview at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on No-reflow phenomenon overview

NICE Guidance on No-reflow phenomenon overview

NHS PRODIGY Guidance

FDA on No-reflow phenomenon overview

CDC on No-reflow phenomenon overview

Books

Books on No-reflow phenomenon overview

News

No-reflow phenomenon overview in the news

Be alerted to news on No-reflow phenomenon overview

News trends on No-reflow phenomenon overview

Commentary

Blogs on No-reflow phenomenon overview

Definitions

Definitions of No-reflow phenomenon overview

Patient Resources / Community

Patient resources on No-reflow phenomenon overview

Discussion groups on No-reflow phenomenon overview

Patient Handouts on No-reflow phenomenon overview

Directions to Hospitals Treating No-reflow phenomenon overview

Risk calculators and risk factors for No-reflow phenomenon overview

Healthcare Provider Resources

Symptoms of No-reflow phenomenon overview

Causes & Risk Factors for No-reflow phenomenon overview

Diagnostic studies for No-reflow phenomenon overview

Treatment of No-reflow phenomenon overview

Continuing Medical Education (CME)

CME Programs on No-reflow phenomenon overview

International

No-reflow phenomenon overview en Espanol

No-reflow phenomenon overview en Francais

Business

No-reflow phenomenon overview in the Marketplace

Patents on No-reflow phenomenon overview

Experimental / Informatics

List of terms related to No-reflow phenomenon overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Jennifer Giuseffi, M.D.; David M. Leder, M.D.; Ayokunle Olubaniyi, M.B,B.S [3]

Overview

Many definitions have been given to this phenomenon based on individual's area of specialty, but the definition that unites all fields was by Kloner et al in 1974 who described the condition as the inability to adequately perfuse myocardium after temporary occlusion of an epicardial coronary artery without evidence of persistent mechanical obstruction, thus implying ongoing myocardial ischaemia. When defined angiographically, it is an acute reduction in coronary flow (TIMI grade 0-1) in the absence of dissection, thrombus, spasm, or high-grade residual stenosis at the original target lesion. In other words, it is the failure of blood to reperfuse an ischemic area after the physical obstruction has been removed or bypassed.[1][2] It has been clearly shown that a complete restoration of epicardial blood flow (TIMI Flow Grade 3) does not correlate with a better myocardial perfusion in achieving better clinical outcomes. Therefore, over the years, attention has shifted towards methods to evaluate myocardial perfusion. A lesser degree of obstruction to coronary blood flow (TIMI grade 2) is sometimes referred to as slow flow. No-reflow is the decline in TIMI flow from TIMI flow 3 or 2 to TIMI flow 1 or 0, which occurs >5 mm distal to the lesion. No-reflow is an important predictor of mortality after PCI [3].

Historical Perspective

This phenomenon was first described by Krug et al [4] during induced myocardial infarction in dog subjects in 1966, but the term 'no-reflow' was first used by Majno and colleagues in 1967 when they observed that brains of rabbits exposed to prolonged ischemia suffered significant changes in the microvasculature which impeded blood flow to the brain cells.

References

  1. "Medscape".
  2. Kishi T, Yamada A, Okamatsu S, Sunagawa K (2007). "Percutaneous coronary arterial thrombectomy for acute myocardial infarction reduces no-reflow phenomenon and protects against left ventricular remodeling related to the proximal left anterior descending and right coronary artery" ([dead link][1]). Int Heart J. 48 (3): 287–302. doi:10.1536/ihj.48.287. PMID 17592194. Unknown parameter |month= ignored (help)
  3. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L; et al. (2003). "No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention". Am Heart J. 145 (1): 42–6. doi:10.1067/mhj.2003.36. PMID 12514653.
  4. Krug, A.; Du Mesnil de Rochemont, G.; Korb, . (1966). "Blood supply of the myocardium after temporary coronary occlusion". Circ Res. 19 (1): 57–62. PMID 5912914. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources